Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-folate receptor alpha antibody-drug conjugate AMT-151

An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting folate receptor alpha (FRa; FolRa; FOLR1) conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-FRa ADC AMT-151, the antibody moiety targets and binds to FRa expressed on tumor cells. Upon cellular uptake and internalization, the cytotoxic agent inhibits tumor cell proliferation through an as of yet undisclosed mechanism of action (MoA). FRa is a glycosylphosphatidylinositol linked cell-surface glycoprotein that is widely expressed in certain cancers while its expression is limited in normal tissues.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-folate receptor alpha ADC AMT-151
anti-FOLR1 ADC AMT-151
anti-FolRa ADC AMT-151
anti-FRa ADC AMT-151
Code name:AMT 151
AMT-151
AMT151
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search